שווי פעילות לרווח לפני ריבית, מסים ופחת Verrica (VRCA)

Verrica Pharmaceuticals (VRCA) is facing a liquidity shortage due to the aggressive promotion of its molluscum therapy, which is depleting capital. This chart illustrates the current share value with an EV/EBITDA of 0.00. Management is effectively optimizing costs and expanding the application of Ycanth, while the company simultaneously invests in specialized transportation for dermatological products to preserve their therapeutic effect during delivery.
Verrica Pharmaceuticals Inc. (VRCA) - פילוחי מדדים ודוחות פיננסיים

The completed R&D phase and Verrica Pharmaceuticals (VRCA) transition to high-margin commercial promotion make the operating model highly scalable. By analyzing the company's EV/EBITDA ratio while accounting for debt load, an investor evaluates the total business value relative to earnings before interest, taxes, depreciation, and amortization, which allows for the determination of the asset's fair price adjusted for the cost of borrowed capital and tax liabilities.